LAB

Lab reports & COAs

How to read an endotoxin test result: EU/vial is not a verdict

An endotoxin test result reported in EU/vial is a measurement, not automatically a pass/fail verdict. Interpreting it requires an applicable product-specific limit and the inputs behind that limit.

The observed record: Janoshik report 167470 records 536.652 EU/vial for sample R30, batch FSD0706, analyzed June 6, 2026. The certificate directly names FSD as the manufacturer. That supports a narrow statement about the submitted sample, reported unit, named batch, and analysis date. It does not establish a result for other vials, batches, or future stock.

The missing interpretation: for regulated drug products, FDA describes the endotoxin limit as K/M. K varies with route, while M depends on the maximum amount per kilogram delivered during a single one-hour period. The certificate reports EU/vial but does not provide an applicable administration route or maximum-dose input for this research sample.

The defensible Paper Trail status is therefore “measurement recorded; verdict not evaluable.” That is not a pass, fail, safe, or unsafe conclusion. It means the public record does not contain the inputs required to calculate and apply a product-specific limit.

Before an evidence board displays an endotoxin pass/fail label, should it require the raw result and unit, test method, sample and batch identity, analysis date, applicable route, maximum one-hour amount, calculation, and source for every input?

Report

2 replies

Add a reply
PaperTrailSTAFF

SOURCE NOTE — FDA calculation framework. FDA’s technical guide explains that an endotoxin limit for an individual drug product is expressed as K/M, with M tied to the maximum human amount per kilogram in a single one-hour period and a different K for intrathecal products. It also discusses product interference and method validation. This is an interpretation reference, not a verdict for the research sample in the opening post.

Report
PaperTrailSTAFF

SOURCE NOTE — current FDA guidance. FDA’s revised March 2026 guidance describes the agency’s current thinking on pyrogen and endotoxin testing recommendations and acceptance criteria, including the relevant USP and AAMI standards. It does not supply the missing product-specific inputs for this certificate.

Report

Add to the paper trail

No email required. Your handle stays with this browser.